Abstract
Rivastigmine hydrogen tartrate is a dual cholinesterase inhibitor widely utilized for the symptomatic management of mild-to-moderate Alzheimer's disease. However, its oral administration is severely limited by short biological half-life, extensive first-pass hepatic metabolism, and pronounced gastrointestinal side effects. Transdermal drug delivery systems offer a promising strategy to overcome these drawbacks, yet the stratum corneum barrier impedes effective cutaneous absorption of hydrophilic molecules. In this study, novel ethosomal gel formulations were developed and evaluated for enhanced transdermal delivery of rivastigmine. Ethosomes composed of soya phosphatidylcholine and ethanol were prepared using the cold method, optimized for vesicle size, entrapment efficiency, and zeta potential, and subsequently incorporated into a Carbopol 934 gel matrix (E-Gel). Ex vivo skin permeation studies using excised rat skin demonstrated that the optimized ethosomal gel exhibited a significantly higher cumulative drug permeation flux (48.52 ± 3.12 µg/cm²/h) compared to conventional hydrogel and commercial patch controls. In vivo pharmacokinetic assessment in Wistar rats revealed a 2.8-fold increase in systemic bioavailability (AUC0-∞) and sustained plasma concentration over 24 hours. Furthermore, in vivo pharmacodynamic evaluation using the Morris water maze in a scopolamine-induced amnesia model confirmed marked cognitive enhancement and significant restoration of brain acetylcholinesterase activity. These results indicate that ethosomal gel represents an advanced dermal platform for sustained transdermal rivastigmine delivery in Alzheimer's therapy.